Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy
Rei Nemoto,1,2 Masahiro Miura,1,2 Takuya Iwasaki,1,2 Hiroshi Goto21Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Ami, Ibaraki, Japan; 2Department of Ophthalmology, Tokyo Medical University, Nishi-Shinjuku, Tokyo, JapanPurpose: We evaluated the 2-year efficacy of comb...
Guardado en:
Autores principales: | Nemoto R, Miura M, Iwasaki T, Goto H |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5a9a36226e494f9d90526e06c51cd2a6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura M, et al.
Publicado: (2013) -
One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy
por: Sakurai M, et al.
Publicado: (2014) -
Combined photodynamic therapy and intravitreal bevacizumab for idiopathic polypoidal choroidal vasculopathy: one-year follow-up
por: Mario R Romano, et al.
Publicado: (2010) -
Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study
por: Takahashi K, et al.
Publicado: (2018) -
Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
por: Azuma K, et al.
Publicado: (2018)